Search research articles
Contact Us
Filters
Showing results (101-110 of 112) with videos related to
Page
of 12
Sort By:
Journal of the National Comprehensive Cancer Network : JNCCN
|
June 8, 2013
Bone cancer
J Sybil Biermann, Douglas R Adkins, Mark Agulnik, et al.
Journal of the National Comprehensive Cancer Network : JNCCN
|
July 5, 2014
Occult primary, version 3.2014
David S Ettinger, Charles R Handorf, Mark Agulnik, et al.
European Journal of Cancer (Oxford, England : 1990)
|
October 10, 2022
A randomised phase II trial of a trivalent ganglioside vaccine targeting GM2, GD2 and GD3 combined with immunological adjuvant OPT-821 versus OPT-821 alone in metastatic sarcoma patients rendered disease-free by surgery
Evan Rosenbaum, Rashmi Chugh, Christopher W Ryan, et al.
The Lancet. Oncology
|
June 28, 2017
Doxorubicin plus evofosfamide versus doxorubicin alone in locally advanced, unresectable or metastatic soft-tissue sarcoma (TH CR-406/SARC021): an international, multicentre, open-label, randomised phase 3 trial
William D Tap, Zsuzsanna Papai, Brian A Van Tine, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
March 28, 2018
Antitumor Activity of Nivolumab in Recurrent and Metastatic Nasopharyngeal Carcinoma: An International, Multicenter Study of the Mayo Clinic Phase 2 Consortium (NCI-9742)
Brigette B Y Ma, Wan-Teck Lim, Boon-Cher Goh, et al.
The Lancet. Oncology
|
March 13, 2013
Cixutumumab and temsirolimus for patients with bone and soft-tissue sarcoma: a multicentre, open-label, phase 2 trial
Gary K Schwartz, William D Tap, Li-Xuan Qin, et al.
Nature Medicine
|
May 26, 2026
Fibroblast growth factor receptor inhibition for succinate dehydrogenase-deficient gastrointestinal stromal tumors: a phase 2 trial
Priscilla Merriam, James J Morrow, Emanuele Mazzola, et al.
Journal of the National Comprehensive Cancer Network : JNCCN
|
February 12, 2017
NCCN Guidelines Insights: Bone Cancer, Version 2.2017
J Sybil Biermann, Warren Chow, Damon R Reed, et al.
Journal of the National Comprehensive Cancer Network : JNCCN
|
November 9, 2022
NCCN Guidelines® Insights: Gastrointestinal Stromal Tumors, Version 2.2022
Margaret von Mehren, John M Kane, Richard F Riedel, et al.
Journal of the National Comprehensive Cancer Network : JNCCN
|
July 13, 2022
Soft Tissue Sarcoma, Version 2.2022, NCCN Clinical Practice Guidelines in Oncology
Margaret von Mehren, John M Kane, Mark Agulnik, et al.
Page
of 12
Search research articles
Search
Showing results (101-110 of 112) with videos related to
Sort By:
Page
of 12
Journal of the National Comprehensive Cancer Network : JNCCN
|
June 8, 2013
Bone cancer
J Sybil Biermann, Douglas R Adkins, Mark Agulnik, et al.
Journal of the National Comprehensive Cancer Network : JNCCN
|
July 5, 2014
Occult primary, version 3.2014
David S Ettinger, Charles R Handorf, Mark Agulnik, et al.
European Journal of Cancer (Oxford, England : 1990)
|
October 10, 2022
A randomised phase II trial of a trivalent ganglioside vaccine targeting GM2, GD2 and GD3 combined with immunological adjuvant OPT-821 versus OPT-821 alone in metastatic sarcoma patients rendered disease-free by surgery
Evan Rosenbaum, Rashmi Chugh, Christopher W Ryan, et al.
The Lancet. Oncology
|
June 28, 2017
Doxorubicin plus evofosfamide versus doxorubicin alone in locally advanced, unresectable or metastatic soft-tissue sarcoma (TH CR-406/SARC021): an international, multicentre, open-label, randomised phase 3 trial
William D Tap, Zsuzsanna Papai, Brian A Van Tine, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
March 28, 2018
Antitumor Activity of Nivolumab in Recurrent and Metastatic Nasopharyngeal Carcinoma: An International, Multicenter Study of the Mayo Clinic Phase 2 Consortium (NCI-9742)
Brigette B Y Ma, Wan-Teck Lim, Boon-Cher Goh, et al.
The Lancet. Oncology
|
March 13, 2013
Cixutumumab and temsirolimus for patients with bone and soft-tissue sarcoma: a multicentre, open-label, phase 2 trial
Gary K Schwartz, William D Tap, Li-Xuan Qin, et al.
Nature Medicine
|
May 26, 2026
Fibroblast growth factor receptor inhibition for succinate dehydrogenase-deficient gastrointestinal stromal tumors: a phase 2 trial
Priscilla Merriam, James J Morrow, Emanuele Mazzola, et al.
Journal of the National Comprehensive Cancer Network : JNCCN
|
February 12, 2017
NCCN Guidelines Insights: Bone Cancer, Version 2.2017
J Sybil Biermann, Warren Chow, Damon R Reed, et al.
Journal of the National Comprehensive Cancer Network : JNCCN
|
November 9, 2022
NCCN Guidelines® Insights: Gastrointestinal Stromal Tumors, Version 2.2022
Margaret von Mehren, John M Kane, Richard F Riedel, et al.
Journal of the National Comprehensive Cancer Network : JNCCN
|
July 13, 2022
Soft Tissue Sarcoma, Version 2.2022, NCCN Clinical Practice Guidelines in Oncology
Margaret von Mehren, John M Kane, Mark Agulnik, et al.
Page
of 12